Cullinan Associates Inc. Has $2.45 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Cullinan Associates Inc. lessened its stake in Boston Scientific Co. (NYSE:BSX) by 5.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,400 shares of the medical equipment provider’s stock after selling 1,600 shares during the quarter. Cullinan Associates Inc.’s holdings in Boston Scientific were worth $2,447,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Quarry LP acquired a new stake in shares of Boston Scientific in the second quarter valued at about $33,000. Czech National Bank raised its holdings in shares of Boston Scientific by 7.1% during the third quarter. Czech National Bank now owns 299,989 shares of the medical equipment provider’s stock valued at $25,139,000 after purchasing an additional 19,833 shares during the period. GAMMA Investing LLC increased its holdings in shares of Boston Scientific by 39.9% during the third quarter. GAMMA Investing LLC now owns 17,432 shares of the medical equipment provider’s stock valued at $1,461,000 after acquiring an additional 4,972 shares in the last quarter. Miracle Mile Advisors LLC lifted its stake in shares of Boston Scientific by 4.0% in the third quarter. Miracle Mile Advisors LLC now owns 5,252 shares of the medical equipment provider’s stock valued at $440,000 after buying an additional 203 shares in the last quarter. Finally, Bank of New Hampshire lifted its stake in Boston Scientific by 52.6% during the 3rd quarter. Bank of New Hampshire now owns 2,235 shares of the medical equipment provider’s stock valued at $187,000 after acquiring an additional 770 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on BSX shares. Mizuho lifted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, October 24th. Morgan Stanley lifted their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday, October 24th. StockNews.com upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, January 29th. TD Cowen increased their target price on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, JPMorgan Chase & Co. raised their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, December 16th. One analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $100.39.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $90.78, for a total value of $633,916.74. Following the transaction, the executive vice president now owns 29,308 shares of the company’s stock, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,989 shares of company stock valued at $2,702,261 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.7 %

Shares of NYSE:BSX opened at $103.11 on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a fifty-two week low of $64.08 and a fifty-two week high of $104.25. The stock has a market cap of $151.97 billion, a price-to-earnings ratio of 85.22, a price-to-earnings-growth ratio of 2.68 and a beta of 0.80. The firm’s 50 day moving average price is $93.47 and its 200 day moving average price is $86.33.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.